ArticleHuman cell2026
Thiolutin attenuates neuroinflammation and neuronal apoptosis by suppressing microglial pyroptosis through NLRP3 inflammasome inhibition after spinal cord injury.
Article in Human cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traumatic spinal cord injury (SCI) initiates a neuroinflammatory response dominated by tissue-resident microglia. Thiolutin (THL) can weaken several inflammatory diseases by blocking the NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome activation. At present, whether THL improves functional recovery after SCI is unclear. Crosstalk between neurons and microglia was simulated by a co-culture system in which microglia were activated by LPS + ATP and treated with THL. Contused SCI mouse models were constructed for studying the efficacy of THL and related mechanisms. Motor function of mice was assessed by BMS scoring, incline plane test, and footprint analysis. Pathological alterations following SCI were determined by hematoxylin-eosin, luxol fast blue, and Nissl staining. Neuronal apoptosis in vitro was assessed by flow cytometry and Tunel staining. The NLRP3 inflammasome activation, inflammatory response, and microglia polarization were assessed by western blot, ELISA, and immunofluorescence. THL treatment repressed microglia pyroptosis-induced neuronal apoptosis and inflammatory response in a co-culture system in vitro. Also, treatment with THL repressed microglial activation and M1-type polarization, along with the NLRP3 inflammasome activation. Furthermore, THL treatment improves motor function of mice with SCI, accompanied by reduced cavity area of the spinal cord, inflammatory response, M1-type microglia polarization, and enhanced remyelination and neuronal regeneration. However, THL treatment did not work in SCI-experienced Nlrp3-/- mice. THL improves motor function following SCI by repressing neuroinflammation and neuronal apoptosis via suppressing NLRP3 inflammasome-mediated microglial polarization and pyroptosis.
Indexed as
Identifiers
42240792What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.